InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,738.17
(
0.00%
)
US TECH 100
19,430.40
(
-0.20%
)
Dow Jones
42,313.00
(
0.00%
)
Brent Oil
71.73
(
0.03%
)
Bitcoin
64,071.70
(
-2.37%
)
Post# of 253253
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120509
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 05/01/2008 3:58:02 PM

Thursday, May 01, 2008 3:58:02 PM

Post# of 253253
IDIX – Musings on the size of an HIV partnership:

According to comments on yesterday’s Morgan Stanley webcast, IDIX expects the partnership deal for its HIV drug, IDX899, to be the biggest HIV-related transaction since GILD’s acquisition of Triangle in 2002, which was a roughly $500M deal.

This is consistent with my prior musings on the partnership potential of IDX899 (#msg-25885594), although I think a $500M deal represents the high end of what is likely rather than the midpoint of the likely range. Here is my reasoning:

Sustiva currently sells more than $1B per year and sales are growing, thanks to its use as a component of the 3-drug combo pill, Atripla, which has become the de facto standard in first-line treatment.

If IDX899 beats Sustiva on efficacy and resistance profile with no deficit in tolerability, a partnership ought to be worth $500M, IMO.

If IDX899 is merely non-inferior to Sustiva in efficacy and tolerability, it may still have a place in the HIV SoC based on its higher barrier to resistance; in this case, an IDX899 partnership ought to be worth about $150M, IMO.

Of course, there are shades of gray between the two cases above depending on the clinical data. Moreover, IDX899 could fail altogether in the phase-2 trial just getting underway, although this is not likely, IMO.

JMHO, FWIW

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up